118 related articles for article (PubMed ID: 7904274)
1. Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma.
Gillett CE; Barnes DM; Camplejohn RS
J Clin Pathol; 1993 Dec; 46(12):1126-8. PubMed ID: 7904274
[TBL] [Abstract][Full Text] [Related]
2. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining.
van Dierendonck JH; Wijsman JH; Keijzer R; van de Velde CJ; Cornelisse CJ
Am J Pathol; 1991 May; 138(5):1165-72. PubMed ID: 1673821
[TBL] [Abstract][Full Text] [Related]
3. Estimation of tumor growth fractions in archival formalin-fixed, paraffin-embedded tissues using two anti-PCNA/Cyclin monoclonal antibodies. Factors affecting reactivity.
Gelb AB; Kamel OW; LeBrun DP; Warnke RA
Am J Pathol; 1992 Dec; 141(6):1453-8. PubMed ID: 1281622
[TBL] [Abstract][Full Text] [Related]
4. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
Siitonen SM; Kallioniemi OP; Isola JJ
Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
[TBL] [Abstract][Full Text] [Related]
5. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis.
Woods AL; Hall PA; Shepherd NA; Hanby AM; Waseem NH; Lane DP; Levison DA
Histopathology; 1991 Jul; 19(1):21-7. PubMed ID: 1680784
[TBL] [Abstract][Full Text] [Related]
6. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.
Aaltomaa S; Lipponen P; Papinaho S; Syrjänen K
J Cancer Res Clin Oncol; 1993; 119(5):288-94. PubMed ID: 8095051
[TBL] [Abstract][Full Text] [Related]
7. Assessment of proliferating cell nuclear antigen (PCNA) in breast cancer using anti-PCNA PC10 and 19A2: correlation with 5-bromo-2'-deoxyuridine or tritiated thymidine labeling and flow cytometric analysis.
He W; Meyer JS; Scrivner DL; Koehm S; Hughes J
Biotech Histochem; 1994 Jul; 69(4):203-12. PubMed ID: 7918835
[TBL] [Abstract][Full Text] [Related]
8. Minimal breast cancer: analysis of proliferative activity using a monoclonal antibody to proliferating cell nuclear antigen (PCNA) and its relationship to histological grade and prognosis.
Lanzafame S; Magro G; Broggi B
Pathologica; 1994 Apr; 86(2):150-6. PubMed ID: 7936757
[TBL] [Abstract][Full Text] [Related]
9. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.
Visakorpi T
J Pathol; 1992 Sep; 168(1):7-13. PubMed ID: 1360498
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation in breast carcinoma assessed by a PCNA grading system and its relation to other prognostic variables.
Betta PG; Bottero G; Pavesi M; Pastormerlo M; Bellinger D; Tallarida F
Surg Oncol; 1993; 2(1):59-63. PubMed ID: 7902763
[TBL] [Abstract][Full Text] [Related]
11. Comparative flow cytometric analysis of proliferating cell nuclear antigen (PCNA) antibodies in human solid neoplasms.
Teague K; el-Naggar A
Cytometry; 1994 Jan; 15(1):21-7. PubMed ID: 7909288
[TBL] [Abstract][Full Text] [Related]
12. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis.
Landberg G; Roos G
Cancer Res; 1991 Sep; 51(17):4570-4. PubMed ID: 1678682
[TBL] [Abstract][Full Text] [Related]
15. KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma.
Sampson SA; Kreipe H; Gillett CE; Smith P; Chaudary MA; Khan A; Wicks K; Parwaresch R; Barnes DM
J Pathol; 1992 Oct; 168(2):179-85. PubMed ID: 1460535
[TBL] [Abstract][Full Text] [Related]
16. Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.
Camplejohn RS; Brock A; Barnes DM; Gillett C; Raikundalia B; Kreipe H; Parwaresch MR
Br J Cancer; 1993 Apr; 67(4):657-62. PubMed ID: 7682430
[TBL] [Abstract][Full Text] [Related]
17. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling.
Kamel OW; LeBrun DP; Davis RE; Berry GJ; Warnke RA
Am J Pathol; 1991 Jun; 138(6):1471-7. PubMed ID: 1675840
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer.
Visscher DW; Wykes S; Kubus J; Crissman JD
Breast Cancer Res Treat; 1992; 22(2):111-8. PubMed ID: 1356517
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10.
Wilson GD; Camplejohn RS; Martindale CA; Brock A; Lane DP; Barnes DM
Eur J Cancer; 1992; 28A(12):2010-7. PubMed ID: 1358156
[TBL] [Abstract][Full Text] [Related]
20. Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma.
Schofield JB; Mansi J; Camplejohn RS; Lane DP; Fisher C
J Clin Pathol; 1992 Aug; 45(8):664-7. PubMed ID: 1357005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
